Fangfang Lai, Ming Ji, Lei Huang, Yunchen Wang, Nina Xue, Tingting Du, Kai Dong, Xiaoqing Yao, Jing Jin, Zhiqiang Feng, Xiaoguang Chen. Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” Acta Pharmaceutica Sinica B 12 (2022) 2845-2858J. Acta Pharmaceutica Sinica B, 2023, 13(7): 3178-3179. DOI: 10.1016/j.apsb.2023.05.003
|
Citation:
|
Fangfang Lai, Ming Ji, Lei Huang, Yunchen Wang, Nina Xue, Tingting Du, Kai Dong, Xiaoqing Yao, Jing Jin, Zhiqiang Feng, Xiaoguang Chen. Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” Acta Pharmaceutica Sinica B 12 (2022) 2845-2858J. Acta Pharmaceutica Sinica B, 2023, 13(7): 3178-3179. DOI: 10.1016/j.apsb.2023.05.003
|
Fangfang Lai, Ming Ji, Lei Huang, Yunchen Wang, Nina Xue, Tingting Du, Kai Dong, Xiaoqing Yao, Jing Jin, Zhiqiang Feng, Xiaoguang Chen. Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” Acta Pharmaceutica Sinica B 12 (2022) 2845-2858J. Acta Pharmaceutica Sinica B, 2023, 13(7): 3178-3179. DOI: 10.1016/j.apsb.2023.05.003
|
Citation:
|
Fangfang Lai, Ming Ji, Lei Huang, Yunchen Wang, Nina Xue, Tingting Du, Kai Dong, Xiaoqing Yao, Jing Jin, Zhiqiang Feng, Xiaoguang Chen. Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” Acta Pharmaceutica Sinica B 12 (2022) 2845-2858J. Acta Pharmaceutica Sinica B, 2023, 13(7): 3178-3179. DOI: 10.1016/j.apsb.2023.05.003
|
DownLoad: